Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2016 October;151(5) > Giornale Italiano di Dermatologia e Venereologia 2016 October;151(5):480-4

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Estratti

GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA

Rivista di Dermatologia e Malattie Sessualmente Trasmesse


Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014


eTOC

 

ORIGINAL ARTICLES  


Giornale Italiano di Dermatologia e Venereologia 2016 October;151(5):480-4

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Cyclosporine: a novel therapeutic approach for Burning Mouth Syndrome

Rosita SARACENO 1, Bruno LORÈ 2, Athanasios PAVLIDIS 1, Maria KARAISKOU 3, Claudio ARCURI 4, 5, Sergio CHIMENTI 1, Roberto MAGNATO 2

1 Department of Dermatology, Tor Vergata University of Rome, Rome, Italy; 2 Department of Otolaryngology and Maxillo-Facial Surgery, F. Tappeneir Hospital, Merano, Italy; 3 School of Dentistry, University of Athens, Athens, Greece; 4 Department of Periodontics, Tor Vergata University of Rome, Rome, Italy; 5 Unit of Odontostomatology, S. Giovanni Calibita, Fatebenefratelli Hospital, Rome, Italy


PDF  


BACKGROUND: The aim of this paper was to evaluate the efficacy and safety of topical cyclosporine applied as mouthwash in the treatment of burning mouth syndrome (BMS).
METHODS: This was a prospective and pilot study conducted by the Department of Dermatology of the University of Rome Tor Vergata. Patients were treated with cyclosporine topically applied as mouthwash for 4 weeks. Clinical improvement was assessed using a 5 grade clinical evaluation scale and a visual analogue scale from 0 to 10 was also used to evaluate the burning symptoms.
RESULTS: Fifteen patients between 22-85 years (61.1±19.3), 11 female and 4 male, with a mean duration of BMS of 12.5 months, completed the study. Five out of 15 patients presented a marked improvement, 6 patients showed a moderate response, 3 patients had a slight improvement and 1 patient did not show any change. The VAS showed a reduction from 8.7 to 3.5. Adverse events were not reported.
CONCLUSIONS: Cyclosporine mouthwash appeared to be safe and beneficial for reducing the burning sensation in patients with BMS representing an alternative therapy in this condition.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail

rositasaraceno@yahoo.it